Concepedia

Publication | Closed Access

Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75

DOI

23

Citations

42

References

2019

Year

Wen‐Yang Hu, Liping Xu, Bailing Chen, Siyu Ou, Kendall Muzzarelli, Danping Hu, Ye Li, Zhe Yang, Donald J. Vander Griend, Gail S. Prins,
The Prostate

Abstract

Novel therapeutic strategy using newly designed 2-75 and related AR antagonist-HDACi hybrid drugs has great potential for effective treatment of CRPC.

References

YearCitations

Page 1